Overview

A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and investigate the efficacy of YRA-1909 in Patients with Rheumatoid Arthritis who are on a stable dose of Methotrexate(MTX) and who have an inadequate response to MTX(MTX-IR).
Phase:
Phase 2
Details
Lead Sponsor:
Yungjin Pharm. Co., Ltd.
Treatments:
Methotrexate